AR066586A1 - Formulacion farmaceutica liquida para proveer nicotina, su uso y fabricacion - Google Patents
Formulacion farmaceutica liquida para proveer nicotina, su uso y fabricacionInfo
- Publication number
- AR066586A1 AR066586A1 ARP080102066A ARP080102066A AR066586A1 AR 066586 A1 AR066586 A1 AR 066586A1 AR P080102066 A ARP080102066 A AR P080102066A AR P080102066 A ARP080102066 A AR P080102066A AR 066586 A1 AR066586 A1 AR 066586A1
- Authority
- AR
- Argentina
- Prior art keywords
- nicotine
- liquid formulation
- disease
- tobacco
- methods
- Prior art date
Links
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 title abstract 12
- 229960002715 nicotine Drugs 0.000 title abstract 9
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 title abstract 9
- 238000004519 manufacturing process Methods 0.000 title abstract 3
- 239000007788 liquid Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 7
- 239000012669 liquid formulation Substances 0.000 abstract 6
- 241000208125 Nicotiana Species 0.000 abstract 3
- 235000002637 Nicotiana tabacum Nutrition 0.000 abstract 3
- 208000025569 Tobacco Use disease Diseases 0.000 abstract 3
- 229920000858 Cyclodextrin Polymers 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 abstract 1
- 206010009900 Colitis ulcerative Diseases 0.000 abstract 1
- 208000011231 Crohn disease Diseases 0.000 abstract 1
- 239000001116 FEMA 4028 Substances 0.000 abstract 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-M L-tartrate(1-) Chemical compound OC(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-M 0.000 abstract 1
- 244000062730 Melissa officinalis Species 0.000 abstract 1
- 235000010654 Melissa officinalis Nutrition 0.000 abstract 1
- 206010057852 Nicotine dependence Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000016620 Tourette disease Diseases 0.000 abstract 1
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 abstract 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 abstract 1
- 229960004853 betadex Drugs 0.000 abstract 1
- 229940001468 citrate Drugs 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000012458 free base Substances 0.000 abstract 1
- 239000000865 liniment Substances 0.000 abstract 1
- 239000006210 lotion Substances 0.000 abstract 1
- 229940049920 malate Drugs 0.000 abstract 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 abstract 1
- 239000007922 nasal spray Substances 0.000 abstract 1
- 239000000668 oral spray Substances 0.000 abstract 1
- 239000006187 pill Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical group O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 abstract 1
- 230000005586 smoking cessation Effects 0.000 abstract 1
- 230000000391 smoking effect Effects 0.000 abstract 1
- 238000007920 subcutaneous administration Methods 0.000 abstract 1
- 238000004260 weight control Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
- A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
- A24B15/10—Chemical features of tobacco products or tobacco substitutes
- A24B15/16—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q13/00—Formulations or additives for perfume preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Birds (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Una formulacion farmacéutica líquida para proveer nicotina en cualquier forma a un sujeto por captacion transdérmica para tratar la dependencia de tabaco y condiciones similares, en donde dicha formulacion es una locion corporal medicada, bálsamo corporal medicado o gel corporal medicado. También se contempla un método para la provision de nicotina, un método para la reduccion de la urgencia de fumar o el uso de tabaco así como métodos para fabricar dicha formulacion líquida, el uso de dicha formulacion líquida para obtener la captacion transdérmica de nicotina a través de la piel de un sujeto, y el uso de nicotina para la produccion de una formulacion líquida para el tratamiento de una enfermedad seleccionado del grupo que consiste en dependencia de tabaco o nicotina, enfermedad de Alzheimer, enfermedad de Crohn, enfermedad de Parkinson, síndrome de Tourette, colitis ulcerosa y control de peso posterior al cese del habito de fumar. Reivindicacion 8: Una formulacion líquida de acuerdo con cualquier reivindicacion precedente, caracterizada porque la nicotina se selecciona del grupo que consiste una sal de nicotina, la forma de base libre de nicotina, un derivado de nicotina, un complejo de inclusion de nicotina o nicotina en cualquier union no covalente; y sus mezclas. Reivindicacion 9: Una formulacion líquida de acuerdo con la reivindicacion 8, en donde el complejo de inclusion de nicotina es un complejo de ciclodextrina, tal como beta-ciclodextrina. Reivindicacion 10: Una formulacion líquida de acuerdo con la reivindicacion 8, en donde la sal de nicotina es sal monotartrato, tartrato de hidrogeno, citrato, malato y/o clorhidrato. Reivindicacion 26: El sistema de acuerdo con la reivindicacion 24 o 25, en donde el medio es un método concomitante o concurrente seleccionado del grupo que consiste en la administracion a través de rocíos bucales, rocíos nasales, parches transdérmicos, dispositivos para inhalacion, pastillas, comprimidos y métodos parenterales, métodos subcutáneos, y métodos transmucosos; o usar tabaco.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/803,745 US20080287507A1 (en) | 2007-05-16 | 2007-05-16 | Nicotine containing toiletry waters |
| SE0701179 | 2007-05-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR066586A1 true AR066586A1 (es) | 2009-09-02 |
Family
ID=40002445
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080102066A AR066586A1 (es) | 2007-05-16 | 2008-05-15 | Formulacion farmaceutica liquida para proveer nicotina, su uso y fabricacion |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20080287507A1 (es) |
| EP (1) | EP2152227A4 (es) |
| JP (1) | JP2010526877A (es) |
| KR (1) | KR20100022049A (es) |
| CN (1) | CN101686922A (es) |
| AR (1) | AR066586A1 (es) |
| AU (1) | AU2008251097B2 (es) |
| BR (1) | BRPI0811858A2 (es) |
| CA (1) | CA2685460A1 (es) |
| MX (1) | MX2009012486A (es) |
| NZ (1) | NZ580730A (es) |
| RU (1) | RU2457822C2 (es) |
| WO (1) | WO2008140373A1 (es) |
| ZA (1) | ZA200908962B (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR071420A1 (es) | 2008-05-01 | 2010-06-16 | Smithkline Beecham Corp | Composicion de pastilla para chupar oral que comprende un principio activo de nicotina y procedimiento para fabricarla |
| WO2011140315A2 (en) * | 2010-05-05 | 2011-11-10 | Northwestern University | Method of reducing proteins misfolding and/or aggregation |
| CN103751060B (zh) * | 2014-01-21 | 2016-03-30 | 江苏中烟工业有限责任公司 | 一种滋润保湿型烟草凝胶剂组合物及其制备方法 |
| IT201800005821A1 (it) * | 2018-05-29 | 2019-11-29 | Miscela con nicotina | |
| GB201817861D0 (en) | 2018-11-01 | 2018-12-19 | Nicoventures Trading Ltd | Gel and crystalline powder |
| ES3034287T3 (en) | 2019-06-07 | 2025-08-14 | Philip Morris Products Sa | Nicotine pouch product |
| CN113208157B (zh) * | 2021-05-07 | 2022-11-04 | 云南中烟工业有限责任公司 | 一种基于内消旋酒石酸烟碱盐胶凝剂的载香超分子凝胶 |
| CN113367375B (zh) * | 2021-05-12 | 2022-11-04 | 云南中烟工业有限责任公司 | 一种基于等酸碱比外消旋扁桃酸尼古丁盐胶凝剂的载香超分子凝胶 |
| CN113880802A (zh) * | 2021-11-09 | 2022-01-04 | 深圳萨特瓦生物科技有限公司 | 酒石酸-尼古丁盐及其制备方法与应用、无水酒石酸晶体的制备方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5016652A (en) * | 1985-04-25 | 1991-05-21 | The Regents Of The University Of California | Method and apparatus for aiding in the reduction of incidence of tobacco smoking |
| GB8615676D0 (en) * | 1986-06-26 | 1986-07-30 | Stoppers Co Ltd | Nicotine containing lozenge |
| IL86170A (en) * | 1987-05-01 | 1992-12-01 | Elan Transdermal Ltd | Preparations and compositions comprising nicotine for percutaneous administration |
| GB9310412D0 (en) * | 1993-05-20 | 1993-07-07 | Danbiosyst Uk | Nasal nicotine system |
| AU676430B2 (en) * | 1994-03-07 | 1997-03-06 | Theratech, Inc. | Drug-containing adhesive composite transdermal delivery device |
| US5810018A (en) * | 1994-12-29 | 1998-09-22 | Monte; Woodrow C. | Method, composition and apparatus for reducing the incidence of cigarette smoking |
| SE9703458D0 (sv) * | 1997-09-25 | 1997-09-25 | Pharmacia & Upjohn Ab | Nicotine compositions and methods of formulation thereof |
| US6479076B2 (en) * | 2001-01-12 | 2002-11-12 | Izhak Blank | Nicotine delivery compositions |
| FR2821270B1 (fr) * | 2001-02-26 | 2003-06-13 | Columbus | Utilisation de nicotine libre pour la fabrication d'une composition anti-cellulitique |
| RU2189245C1 (ru) * | 2001-10-01 | 2002-09-20 | Закрытое акционерное общество "Косметический центр "ЛАКРИМА" | Очищающий косметический гель |
| US7105173B1 (en) * | 2002-03-21 | 2006-09-12 | Rolling Kenneth J | Nicotine replacement applique |
| US20040002520A1 (en) * | 2002-07-01 | 2004-01-01 | Soderlund Patrick L. | Composition and method for cessation of Nicotine cravings |
| GB0317868D0 (en) * | 2003-07-30 | 2003-09-03 | Disperse Ltd | Biliquid foams with a high alcohol content and products formulated therefrom |
| ES2334681T3 (es) * | 2004-03-19 | 2010-03-15 | Mcneil Ab | Medios para la administracion transdermica de nicotina. |
-
2007
- 2007-05-16 US US11/803,745 patent/US20080287507A1/en not_active Abandoned
-
2008
- 2008-04-21 CN CN200880015889A patent/CN101686922A/zh active Pending
- 2008-04-21 JP JP2010508333A patent/JP2010526877A/ja active Pending
- 2008-04-21 RU RU2009146578/15A patent/RU2457822C2/ru not_active IP Right Cessation
- 2008-04-21 CA CA002685460A patent/CA2685460A1/en not_active Abandoned
- 2008-04-21 MX MX2009012486A patent/MX2009012486A/es not_active Application Discontinuation
- 2008-04-21 WO PCT/SE2008/000279 patent/WO2008140373A1/en not_active Ceased
- 2008-04-21 KR KR1020097026275A patent/KR20100022049A/ko not_active Ceased
- 2008-04-21 EP EP08741853A patent/EP2152227A4/en not_active Ceased
- 2008-04-21 BR BRPI0811858-2A2A patent/BRPI0811858A2/pt not_active Application Discontinuation
- 2008-04-21 NZ NZ580730A patent/NZ580730A/xx not_active IP Right Cessation
- 2008-04-21 AU AU2008251097A patent/AU2008251097B2/en not_active Ceased
- 2008-05-15 AR ARP080102066A patent/AR066586A1/es not_active Application Discontinuation
-
2009
- 2009-12-15 ZA ZA2009/08962A patent/ZA200908962B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200908962B (en) | 2011-02-23 |
| CA2685460A1 (en) | 2008-11-20 |
| EP2152227A4 (en) | 2012-11-07 |
| AU2008251097A1 (en) | 2008-11-20 |
| MX2009012486A (es) | 2009-12-02 |
| CN101686922A (zh) | 2010-03-31 |
| RU2009146578A (ru) | 2011-06-27 |
| WO2008140373A1 (en) | 2008-11-20 |
| JP2010526877A (ja) | 2010-08-05 |
| US20080287507A1 (en) | 2008-11-20 |
| AU2008251097B2 (en) | 2013-06-27 |
| NZ580730A (en) | 2013-04-26 |
| KR20100022049A (ko) | 2010-02-26 |
| EP2152227A1 (en) | 2010-02-17 |
| RU2457822C2 (ru) | 2012-08-10 |
| BRPI0811858A2 (pt) | 2014-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR066586A1 (es) | Formulacion farmaceutica liquida para proveer nicotina, su uso y fabricacion | |
| AR060932A1 (es) | Producto y su uso y elaboracion | |
| NZ595467A (en) | Sublingual pharmaceutical composition comprising a neutral oil | |
| DK2574167T3 (en) | LIQUID NOSE SPRAY CONTAINING low-dose naltrexone | |
| JP2013527167A5 (es) | ||
| NZ604029A (en) | Methods of treating bladder cancer | |
| CA2963423A1 (en) | Device and method for delivery of a medicament | |
| FR2979539B1 (fr) | Composition sterile dermo-injectable | |
| MX2011014025A (es) | Composicion farmaceutica que comprende sales de rotigotina (acidio o na), especialmente para iontoforesis. | |
| WO2009088838A3 (en) | Triarylmethane analogs and their use in treating cancers | |
| CN109574993A (zh) | 取代的嘧啶哌嗪化合物及其用途 | |
| AR088267A1 (es) | Derivados, de los factores de coagulacion sanguinea vii y viia, conjugados y complejos que comprenden a los mismos y sus usos | |
| PH12018550210A1 (en) | Oral dosage form with drug composition, barrier layer and drug layer | |
| MX2010009270A (es) | Compuestos y metodos para la prevencion o tratamiento de reestenosis. | |
| EA201290603A1 (ru) | Способ лечения | |
| BR112015030623A2 (pt) | agentes citotóxicos para o tratamento de câncer | |
| PL2244703T3 (pl) | Lekarstwo, jego wytwarzanie i zastosowanie w leczeniu bolesnych neuropatii | |
| RU2010143715A (ru) | Терапевтическое применение новых фармацевтических препаратов, содержащих противоопухолевые лекарственные средства, связанные с гиалуроновой кислотой, в лечении неоплазий | |
| PH12015500653B1 (en) | Combination drug comprising gemigliptin and metformin, and method for the preparation thereof | |
| WO2011024168A3 (en) | Sustained release delivery systems for the prevention and treatment of head and neck cancers | |
| BR112015030664A2 (pt) | combinação farmacêutica de um inibidor de pi3k e um agente desestabilizador de microtúbulos | |
| MX2009007889A (es) | Derivados de 3-cinnolincarboxamida y su uso para el tratamiento del cancer. | |
| JP2010155867A5 (es) | ||
| CL2011000805A1 (es) | Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion de lictus en pacientes que padecen fibrilacion auricular. | |
| CL2009000478A1 (es) | Composicion farmaceutica que comprende piracetam o una sal del mismo, l-carnitina y un vehiculo; proceso de preparacion de la composicion; y su uso para el tratamiento y/o prevencion de trastornos mitocondriales relacionados con efectos colaterales inducidos por farmacos, tal como enfermedad de alzheimer o mal de parkinson. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |